PK150

• CAT Number: I017354
• CAS Number: 2165324-62-7
• Molecular Formula: C₁₅H₈ClF₅N₂O₃
• Molecular Weight: 394.68
• Purity: ≥95%
• Target: Bacterial
• Storage: -20°C
• IUPAC Name: 1-[4-chloro-3-(trifluoromethyl)phenyl]-3-(2,2-difluoro-1,3-benzodioxol-5-yl)urea
• InChI: InChI=1S/C15H8ClF5N2O3/c16-10-3-1-7(5-9(10)14(17,18)19)22-13(24)23-8-2-4-11-12(6-8)26-15(20,21)25-11/h1-6H,(H2,22,23,24)
• InChIKey: SHPYXCLUNMOJOB-UHFFFAOYSA-N
• SMILES: C1=CC2=C(C=C1NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)OC(O2)(F)F

PK150（Cat No.:I017354） is an analogue of Sorafenib that exhibits oral bioavailability and demonstrates potent antibacterial activity against various pathogenic strains at submicromolar concentrations. It effectively inhibits Gram-positive bacteria including Methicillin-sensitive S. aureus (MSSA), Methicillin-resistant S. aureus (MRSA), and Vancomycin intermediate S. aureus (VISA), with minimum inhibitory concentrations (MICs) ranging from 0.3 to 1 µM. These findings suggest that PK150 holds promise as a potential antibacterial agent against resistant strains of S. aureus, highlighting its potential for further development and investigation in combating bacterial infections.

Reference

[1]. Le P, et al. Repurposing human kinase inhibitors to create an antibiotic active against drug-resistant Staphylococcus aureus, persisters and biofilms. Nat Chem. 2019 Dec 16.